Since assuming office for a second term, President Trump and officials within his administration have instituted a sweeping series of policy actions through the Department of Health and Human Services (HHS) that have significantly altered the landscape of public health across the United States. This resource tracks these key policy actions, executive orders, regulatory shifts, and structural reorganizations in the chronological order in which they were first issued, reported, or announced, while also detailing subsequent developments, legal challenges, and related outcomes.
While this comprehensive tracker captures many of the most high-profile and consequential decisions shaping federal health policy, it is not exhaustive of every federal policy change enacted during this period. Numerous actions originating outside of HHS also carry profound implications for public health, though they fall outside the direct scope of this specific overview. Additional specialized resources regarding administrative actions targeting global health, LGBTQ+ health, and mental health and substance abuse are tracked separately.
The policy shifts began immediately upon the inauguration of President Trump’s second term, marked by executive orders that precipitated the rapid removal of numerous federal websites and health databases. In the opening days of his administration, the President issued directives revoking various prior orders while instituting strict new federal guidance concerning gender ideology, diversity, equity, and inclusion (DEI) programs, and merit-based opportunities. These executive actions had an immediate operational impact on public health communication, prompting HHS to remove thousands of pages and databases addressing DEI, LGBTQ+ initiatives, reproductive health, HIV/AIDS research, and health disparities. This led to a legal challenge by the Washington State Medical Association and other plaintiffs. Months later, in September 2025, the administration reached an agreement to restore these removed public health websites and data repositories to the versions that existed on January 29, 2025.
Administrative restructuring and funding adjustments quickly followed across multiple federal agencies. On February 7, 2025, the National Institutes of Health (NIH) announced a major policy shift regarding "indirect cost" funding provided to grant recipients to support administrative and facilities overhead. The NIH instituted a new 15% standard indirect cost rate for all new and existing grants. This reduction triggered immediate legal pushback from state attorneys general, resulting in a temporary restraining order, a preliminary injunction, and eventually a permanent injunction issued by a federal judge on April 4, 2025, keeping prior rates in place pending ongoing appeals.
Following the Senate’s 52-48 partisan confirmation of Robert F. Kennedy, Jr. as HHS Secretary on February 13, 2025, the administration issued an Executive Order establishing the "Make America Healthy Again" (MAHA) policy agenda and the MAHA Commission, naming Secretary Kennedy as its chair. The initiative directed federal agencies to combat childhood chronic disease, mental health disorders, obesity, and diabetes, setting strict timelines for the Commission to deliver a comprehensive assessment and strategy. Concurrently, the administration, working in tandem with the Department of Government Efficiency (DOGE), initiated substantial workforce reductions and restructurings across federal health agencies.
In mid-February, the White House issued an Executive Order barring federal funding to any K-12 school, educational agency, or higher education institution enforcing COVID-19 vaccine mandates for in-person attendance. At the time, while no states mandated COVID-19 vaccines for K-12 students, approximately 15 colleges maintained such requirements; however, by mid-March 2025, all of those institutions had dropped their mandates. Shortly thereafter, during his official welcome ceremony, Secretary Kennedy outlined his broader public health priorities, which included scrutinizing the childhood vaccine schedule, addressing corporate corruption, and focusing on a chronic disease epidemic linked by the administration to environmental factors, food additives, and pharmaceuticals.
Regulatory procedures underwent a profound transformation on February 28, 2025, when Secretary Kennedy issued a new rule rescinding the longstanding "Richardson Waiver" from 1971. This change aligned HHS rulemaking strictly with the Administrative Procedure Act, exempting matters related to agency management, personnel, loans, grants, benefits, and contracts from traditional public notice and comment periods. While proponents argued the change would streamline agency operations, critics, including several lawmakers and public health organizations, warned it would diminish public visibility and input on major policy shifts.
As the spring of 2025 progressed, the administration launched several targeted public health studies and policy revisions. HHS announced that the CDC would investigate the rising prevalence of autism diagnoses, a topic further emphasized in September when the administration suggested a link between prenatal acetaminophen use and autism—a claim that drew swift pushback from medical and scientific experts. Simultaneously, the FDA released its 2025–2026 influenza vaccine composition guidance without consulting its external advisory committee, the Vaccines and Related Biological Products Advisory Committee (VRBPAC), breaking with decades of precedent and bypassing technical coordination with World Health Organization experts following the U.S. withdrawal from the UN agency.
In March 2025, the NIH initiated the termination of numerous research grants focusing on HIV prevention, adolescent treatment, and pre-exposure prophylaxis (PrEP). Around the same time, HHS removed the 2024 Surgeon General advisory declaring gun violence a public health crisis from its website, shut down the White House Office of Gun Violence Prevention, and reduced staffing at the CDC’s Injury Center and Division of Violence Prevention. Furthermore, HHS and the CDC sought to recall $11.4 billion in supplemental COVID-19 and public health grants previously distributed to state and local health departments. This clawback effort faced an immediate legal challenge from a coalition of 23 Democratic-led states, resulting in federal court orders that ultimately restored nearly 80% of the targeted funds to the victorious plaintiff states by late August.
A sweeping reorganization of HHS was announced on March 27, 2025, aiming to combine several key agencies into a proposed Administration for a Healthy America (AHA) and eliminate 10,000 full-time positions as part of broader federal workforce optimization. This mass layoff effort faced immediate legal challenges from a coalition of states. Although lower courts initially paused the firings, the U.S. Supreme Court ultimately overturned those decisions in July 2025, allowing the administration’s workforce reductions to proceed past the 20,000 mark. While certain structural closures—such as the HHS Office of Infectious Diseases and HIV Policy—were enacted, the broader statutory formation of the AHA required congressional approval that was not forthcoming.
Financial pressures and regulatory overhauls continued into April 2025. HHS temporarily withheld Title X family planning service grants from approximately one in five current recipients, affecting nearly 900 clinics nationwide, though funding was eventually restored to several non-profit grantees while Planned Parenthood affiliates remained cut off. The federal government also terminated its three-decade participation in the "Safe to Sleep" infant mortality reduction campaign. Additionally, the CDC was ordered to cut its contract spending by $2.9 billion, and Secretary Kennedy announced an initiative to review federal water fluoridation policies, encouraging states to ban the additive—a move that prompted legislative bans in Utah and Florida.
The FDA instituted several significant pharmaceutical oversight changes in the spring and summer of 2025. It required Pfizer and Moderna to expand warning labels on their mRNA COVID-19 vaccines regarding myocarditis risks, initiated a phased federal transition away from petroleum-based food dyes in the U.S. supply chain, and announced that future COVID-19 booster approvals for non-high-risk populations would require evidence from randomized, placebo-controlled clinical trials rather than immune-response data alone. In May, HHS redirected $500 million from previous COVID-19 vaccine initiatives toward a "Generation Gold Standard" universal vaccine platform. Concurrently, the White House issued an executive order tightening oversight and restricting federal funding for "gain-of-function" biological research.
Vaccine recommendations and committee structures underwent historic disruptions beginning in late May 2025, when Secretary Kennedy announced via social media that COVID-19 vaccines for healthy children and pregnant women were being removed from the CDC’s recommended immunization schedule. This bypass of the Advisory Committee on Immunization Practices (ACIP) triggered a lawsuit from a coalition of medical organizations. Shortly thereafter, on June 9, Secretary Kennedy dismissed all 17 sitting members of ACIP—an unprecedented move—and subsequently appointed new members who had previously expressed skepticism regarding certain vaccine policies. The newly constituted ACIP later voted to recommend individual shared decision-making for COVID-19 and hepatitis B vaccines, remove the combination MMRV vaccine recommendation for young children in favor of separate doses, and end recommendations for thimerosal in multi-dose flu vials.
The administration also altered sex education and teen pregnancy prevention program requirements, withholding funds from jurisdictions that declined to remove gender inclusivity promotion from their curricula. In July 2025, the CDC deactivated its national emergency response for H5N1 bird flu, shifting to monthly reporting amid declining reported human cases, though wild bird outbreaks began climbing again in the autumn. Simultaneously, Secretary Kennedy canceled scheduled meetings of the U.S. Preventive Services Task Force (USPSTF), leaving several member vacancies unfilled and raising questions regarding future preventive health coverage mandates under the Affordable Care Act.
Leadership turbulence marked the CDC during the summer of 2025 when Susan Monarez, who had been sworn in as CDC Director on July 31, was removed from her post less than a month later after declining to implement mass personnel firings without cause and refusing blanket approvals for vaccine policy changes. Deputy HHS Secretary Jim O’Neill was subsequently named acting CDC Director. Concurrently, HHS barred professional medical organizations such as the American Academy of Pediatrics and the American Medical Association from participating in ACIP working group meetings, and announced the wind-down of nearly $500 million in BARDA funding dedicated to mRNA vaccine research. Conversely, the administration officially reinstated the long-defunct Task Force on Safer Childhood Vaccines within the NIH.
The MAHA Commission released its comprehensive national strategy in September 2025, detailing over 120 initiatives aimed at curbing childhood chronic disease through dietary reforms, reduced chemical exposure, and altered federal research priorities. In parallel, the administration announced a series of actions targeting autism spectrum disorder, which included FDA authorization for leucovorin as an autism symptom treatment, warnings regarding prenatal acetaminophen use, and controversial changes to CDC website language stating that a link between infant vaccines and autism could not be ruled out—a statement sharply criticized by major medical and scientific associations.
As the year concluded, additional regulatory actions were finalized. The FDA announced upcoming warnings for long-term opioid use and initiated the removal of black box warnings from menopausal hormone replacement therapy products. Meanwhile, federal agencies grappled with the operational impacts of a government shutdown in October 2025, which saw thousands of federal worker layoffs concentrated heavily at the CDC.
Heading into 2026, the administration continued its aggressive restructuring of federal public health guidelines. In January 2026, HHS issued a memo significantly trimming the routine childhood immunization schedule down from 17 recommended diseases to 11, moving several vaccines—including those for hepatitis A, hepatitis B, influenza, and rotavirus—into the "shared clinical decision-making" category. Although this schedule was subsequently stayed by a federal judge in March 2026 following legal challenges from pediatric associations, the administration appealed the decision. Further legal battles erupted in February 2026 when the administration ordered the CDC to rescind $600 million in public health and HIV/STD prevention grants directed toward four Democratic-led states, prompting a successful temporary restraining order from a federal court.
Throughout the spring and summer of 2026, regulatory and advisory frameworks continued to evolve. The FDA announced a general policy shift to accept single clinical trials rather than two for certain drug approvals, and launched specialized frameworks for ultra-rare diseases. However, internal friction persisted over data transparency, notably when CDC leadership temporarily delayed the publication of a winter 2025–2026 COVID-19 vaccine effectiveness study that demonstrated substantial reductions in emergency visits and hospitalizations.
In May 2026, the White House issued a follow-up Executive Order instructing HHS to further align U.S. core childhood vaccine recommendations with peer developed nations, while the administration published a revised ACIP charter giving the CDC Director tighter oversight and broadening member expertise criteria. By late June 2026, Secretary Kennedy formally terminated remaining COVID-19 Emergency Use Authorization declarations for medical devices and therapeutic products, citing a lack of ongoing necessity.
The administration rounded out the summer and early fall of 2026 by naming eight new members to the long-dormant USPSTF, altering official CDC mortality tracking methodology for the national measles epidemic to rely on direct National Center for Health Statistics review, and launching agency-wide initiatives dedicated to studying and compensating reported vaccine injuries through modernized reporting systems and dedicated clinical care and research at the NIH.
